Life sciences company Revvity (NYSE:RVTY) announced in Q1 CY2025, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0 ...

Revvity, Inc. RVTY recently introduced Signals Xynthetica, a next-generation AI-augmented design platform aimed at transforming molecular and materials discovery across scientific industries.

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Earlier this week, Revvity reported stronger-than-expected Q4 2025 results, with Diagnostics delivering 10% reported revenue growth and management issuing upbeat full-year 2026 guidance calling for ...

WALTHAM, Mass.--(BUSINESS WIRE)--#LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate ...

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (RVTY) (NYSE: RVTY), today announced it will host an Investor Day on Thursday, November 21, 2024 at 9:00 a.m. PT which will feature presentations by ...